Form 6-K GENETIC TECHNOLOGIES For: Jul 05

---

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

---

 

 

FORM 6-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

 

dated July 5, 2022

 

Commission File Number 0-51504

 

GENETIC TECHNOLOGIES LIMITED

(Exact Name as Specified in its Charter)

 

N/A

(Translation of Registrant’s Name)

 

60-66 Hanover Street

Fitzroy

Victoria 3065 Australia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ☐ No ☒

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: July 5, 2022

 

	GENETIC TECHNOLOGIES LIMITED
	By:	/s/ Mike Tonroe
	Name:	Mike Tonroe
	Title:	Company Secretary

 

 

EXHIBIT INDEX

 

Exhibit		Description of Exhibit
99.47		20220705 – EasyDNA expands Indian and European markets FINAL

 

 

 

Exhbit 99.47

 

 

EasyDNA expands Indian and European markets; launching NIPT, Carrier testing and DNA storage

 

Melbourne, Australia, 5 July 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the Company’s recently acquired, EasyDNA, has embarked on a significant expansion in both its test portfolio and geographical reach.

 

Highlights:

 

	●	Carrier Testing and Non-Invasive Prenatal Tests (NIPT) available to our European market
	●	India team has partnered with stud farms to identify equine chain of custody
	●	Launched DNA storage facility in NATA1 and CLIA2 certified laboratory

 

EasyDNA has expanded the availability on its websites of Carrier Testing and Non-Invasive Prenatal Tests (NIPT) into Europe, the second biggest healthcare market in the world. Demand in this region for more informed choices regarding fertility and pregnancy is providing a strong foundation for the Company’s portfolio which includes pre-conception and prenatal testing.

 

EasyDNA India has partnered with a number of stud farms providing reliable, independent and comprehensive chain of custody for equine paternity testing which includes storage of profile data. EasyDNA has received initial samples and commenced testing, with results to be featured in Indian Stud Book³. Horse racing and associated stud farming is a significant business in the world’s second largest population enabling EasyDNA to leverage the Company’s existing paternity infrastructure.

 

EasyDNA has recently launched the capability to store DNA in the Company’s NATA approved facility. According to Forensic Science Review, Nucleic acid sample storage is of paramount importance in forensic science as well as in epidemiological, clinical, and genetic laboratories. EasyDNA is offering a “best in class” solution to store DNA samples for up to 15 years, including with complete chain of custody, enabling future legal testing.

 

GTG’s CEO, Simon Morriss said “These incremental growth initiatives being undertaken by the EasyDNA team are exciting and expand the Company’s direct-to-consumer offering to new markets and channels ensuring GTG’s continuous revenue growth.”

 

¹ National Association of Testing Authorities, Australia (NATA)

² Clinical Laboratory Improvement Amendments (CLIA) - Regulates laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS)

³ Indian Stud Book http://indianstudbook.com/publications.php

 

<End>

 

Authorised for release by the board of directors of Genetic Technologies Limited

 

Genetic Technologies Limited	60-66 Hanover Street
www.genetype.com	Fitzroy Victoria 3065
[email protected]	Australia
ABN 17 009 212 328	+61 3 8412 7000

 

 

 

Enquiries

 

Investor Relations

Justin Foord

Market Eye

M: +61 402 600 691

E: [email protected]

 

About Genetic Technologies Limited

 

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company’s Polygenic Risk Scores (PRS) platform is a proprietary risk stratification platform developed over the past decade integrating clinical and genetic risk delivering actionable outcomes from physicians and individuals. Leading the world in risk prediction in Oncology, Cardiovascular and Metabolic diseases. Genetic Technologies continues to develop a pipeline of risk assessment products. For more information, please visit www.genetype.com

 

Genetic Technologies Limited	60-66 Hanover Street
www.genetype.com	Fitzroy Victoria 3065
[email protected]	Australia
ABN 17 009 212 328	+61 3 8412 7000

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Genetic Technologies (GENE) Files New Coronavirus Patent - Patent Grants
• CSAA Took Advantage of Pandemic, Overcharged Policyholders by at Least $150 Million for Auto Insurance, Policyholder Lawsuit Says
• Maquia Capital Acquisition Corporation Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination